Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles

Stem cells hold great potential as cell-based therapies to promote vascularization and tissue regeneration. However, the use of stem cells alone to promote angiogenesis remains limited because of insufficient expression of angiogenic factors and low cell viability after transplantation. Here, we have developed vascular endothelial growth factor (VEGF) high-expressing, transiently modified stem cells for the purposes of promoting angiogenesis. Nonviral, biodegradable polymeric nanoparticles were developed to deliver hVEGF gene to human mesenchymal stem cells (hMSCs) and human embryonic stem cell-derived cells (hESdCs). Treated stem cells demonstrated markedly enhanced hVEGF production, cell viability, and engraftment into target tissues. S.c. implantation of scaffolds seeded with VEGF-expressing stem cells (hMSCs and hESdCs) led to 2- to 4-fold-higher vessel densities 2 weeks after implantation, compared with control cells or cells transfected with VEGF by using Lipofectamine 2000, a leading commercial reagent. Four weeks after intramuscular injection into mouse ischemic hindlimbs, genetically modified hMSCs substantially enhanced angiogenesis and limb salvage while reducing muscle degeneration and tissue fibrosis. These results indicate that stem cells engineered with biodegradable polymer nanoparticles may be therapeutic tools for vascularizing tissue constructs and treating ischemic disease.

[1]  Seung‐Woo Cho,et al.  Gene delivery to human adult and embryonic cell-derived stem cells using biodegradable nanoparticulate polymeric vectors , 2009, Gene Therapy.

[2]  K. Houkin,et al.  Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia , 2009, Experimental Neurology.

[3]  Stefanie Dimmeler,et al.  Homing and engraftment of progenitor cells: a prerequisite for cell therapy. , 2008, Journal of molecular and cellular cardiology.

[4]  Meijing Wang,et al.  Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions. , 2008, American journal of physiology. Heart and circulatory physiology.

[5]  Eun-Suk Kim,et al.  Material-based deployment enhances efficacy of endothelial progenitor cells , 2008, Proceedings of the National Academy of Sciences.

[6]  Cato T Laurencin,et al.  Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: A combined gene therapy–cell transplantation approach , 2008, Proceedings of the National Academy of Sciences.

[7]  Jae Min Lim,et al.  Improvement of Postnatal Neovascularization by Human Embryonic Stem Cell–Derived Endothelial-Like Cell Transplantation in a Mouse Model of Hindlimb Ischemia , 2007, Circulation.

[8]  H. Uludaǧ,et al.  A comparative evaluation of poly-L-lysine-palmitic acid and Lipofectamine 2000 for plasmid delivery to bone marrow stromal cells. , 2007, Biomaterials.

[9]  D. Lauffenburger,et al.  Combinatorial Modification of Degradable Polymers Enables Transfection of Human Cells Comparable to Adenovirus , 2007 .

[10]  L. Ye,et al.  Transplantation of Nanoparticle Transfected Skeletal Myoblasts Overexpressing Vascular Endothelial Growth Factor-165 for Cardiac Repair , 2007, Circulation.

[11]  Nan Ma,et al.  Bcl‐2 Engineered MSCs Inhibited Apoptosis and Improved Heart Function , 2007, Stem cells.

[12]  Robert Langer,et al.  Rapid Optimization of Gene Delivery by Parallel End-modification of Poly(β-amino ester)s. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  L. Ye,et al.  Directing endothelial differentiation of human embryonic stem cells via transduction with an adenoviral vector expressing the VEGF165 gene , 2007, The journal of gene medicine.

[14]  H. Haider,et al.  Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. , 2007, Journal of molecular and cellular cardiology.

[15]  Daniel G. Anderson,et al.  Rapid optimization of gene delivery by parallel end-modification of poly(beta-amino ester)s. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Nathaniel S. Hwang,et al.  Chondrogenic differentiation of human embryonic stem cell-derived cells in arginine-glycine-aspartate-modified hydrogels. , 2006, Tissue engineering.

[17]  M. Baccarani,et al.  Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow–Derived Mesenchymal Stem Cells , 2006, Stem cells.

[18]  Daniel W. Pack,et al.  Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.

[19]  K. Ohta,et al.  Vascular Endothelial Growth Factor–Expressing Mesenchymal Stem Cell Transplantation for the Treatment of Acute Myocardial Infarction , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Ingwall,et al.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells , 2005, Nature Medicine.

[21]  Daniel G. Anderson,et al.  Structure/property studies of polymeric gene delivery using a library of poly(β-amino esters). , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Daniel G. Anderson,et al.  Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  M. Burnett,et al.  Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms , 2004, Circulation research.

[24]  R. David,et al.  Stem-cell homing and tissue regeneration in ischaemic cardiomyopathy , 2003, The Lancet.

[25]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[26]  Y. Mori,et al.  Angiogenesis by Implantation of Peripheral Blood Mononuclear Cells and Platelets Into Ischemic Limbs , 2002, Circulation.

[27]  J. Isner,et al.  Endothelial Progenitor Cell Vascular Endothelial Growth Factor Gene Transfer for Vascular Regeneration , 2002, Circulation.

[28]  Paul D. Kessler,et al.  Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart , 2002, Circulation.

[29]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[30]  S. Epstein,et al.  Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. , 2001, Cardiovascular research.

[31]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[32]  D J Mooney,et al.  Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[33]  H. Kleinman,et al.  Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. , 1999, The American journal of pathology.

[34]  H. Kleinman,et al.  Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. , 1999, The American journal of pathology.